Evidence map›Paper›PMID 33088327›Full record

ArticleResearch in pharmaceutical sciences2020

Comparison of the cytotoxic effects of different fractions of

Elham Ramazani, Zahra Tayarani-Najaran, Yalda Shokoohinia, Mahdi Mojarrab

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Neobaicalein, a flavonoid from theIranian journal of basic medical sciences · 2023
    Article
  2. Cytotoxic Activity and Phytochemical Analysis ofIranian journal of pharmaceutical research : IJPR · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Elham RamazaniDepartment of Cell and Molecular Biology, Faculty of Science, Kosar University of Bojnord, Bojnord, I.R. Iran.
Zahra Tayarani-NajaranBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.
Yalda ShokoohiniaPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, I.R. Iran.
Mahdi MojarrabPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, I.R. Iran.
Mashhad University of Medical Sciences · IRKermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeEXPERIMENTAL APPROACH: The cytotoxic effects of 16 (F1-F16), 11 (F1'-F11') and 10 (F1"-F10") fractions, on B16/F10, PC3, and MCF7 cell lines were assessed using resazurin to measure viability and propidium iodide staining (sub G1) and flow cytometry to detect apoptosis. FINDINGS /

resultsThe results showed that, some fractions at 100 μg/mL decreased cell viability. F2" in B16/F10 cells, F2, F4-F6, F10', F11', and F2" in PC3 cells, and F10', F11', and F2" in MCF7 significantly decreased cell viability in a concentration-dependent manner (12.5-50 μg/mL). Among different fractions, F2" demonstrated the most potent cytotoxic effects on cancer cell lines ( CONCLUSION AND IMPLICATIONS:

Indexed as

ApoptosisArtemisia biennisArtemisia ciniformisCytotoxicViability

Identifiers

PMID33088327
PMCPMC7540818
OpenAlexW3038554537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.